Glycyl-L-Glutamine (Beta-endorphin 30-31)
Beta-endorphin C-terminal dipeptide investigated for opioid-tolerance modulation and CNS effects.
Scientific Overview
Glycyl-L-glutamine (Gly-Gln, beta-endorphin 30-31) is the C-terminal cleavage product of beta-endorphin. Animal studies (Goldstein, Unterwald, and others) suggest it modulates opioid tolerance and respiratory drive without classical opioid-receptor binding. Best supported as a research tool rather than a therapeutic; no clinical indication.
Key Research Benefits
- ✓Modulates opioid tolerance (preclinical)
- ✓Possible respiratory drive
- ✓Studied in addiction models
Potential Side Effects
Research Protocols
Common DosagesResearch
“Animal studies 1-10 mg/kg”
Dose Calculator
🧮 Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.10 mL on a U-100 syringe
Explore Glycyl-L-Glutamine (Beta-endorphin 30-31)
Where to source
Vendors with public COAs that stock this category. Affiliate links are disclosed.
- Limitless Life NootropicsFL-based research-peptide supplier with Janoshik third-party COAs and a public affiliate program at ~20%.COA: JanoshikAffiliate disclosed
- SwissChems60+ peptide catalog with Janoshik COAs; weekly affiliate payouts.COA: JanoshikAffiliate disclosed
- Amino ClubEU/US-facing vendor with a 20% first-order / 10% recurring affiliate model.COA: Third-partyAffiliate disclosed
Molecular Profile
Quick Reference
- Status
- Research Compound
- Category
- Cognitive
- Common Dosage
- Not established
- N/A
Strictly for research purposes. Not for human consumption.
Related tools
Medical Disclaimer
Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.